Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of brivaracetam adjunctive therapy in epilepsy
2014-004397-42Phase 3
- Sponsor
- UCB
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy, Focal Onset Epilepsy and idiopathic epilepsy (IGE), sponsored by UCB. Primary endpoint: Incidence of Treatment-Emergent Adverse Events.
02
Drugs
brivaracetam
03
Conditions
epilepsyFocal Onset Epilepsyidiopathic epilepsy (IGE)
Beyond the preview
Go deeper on 2014-004397-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004397-42.